BASF opens new construction chemicals production site in India Today (June 12, 2008), the BASF Construction Chemicals division is to open a plant for concrete admixtures in Kolkata (Calcutta), East India. The new plant is BASF's response to soaring Indian construction industry demand for high-quality concrete admixtures in East India, North East India and West Bengal. Kolkata is BASF's fourth production site for construction chemicals in India.
SUBMIT your ARTICLE or NEWS ITEM, please send together with any photographs by email.
NEWS
ARTICLES
SUBMIT YOUR NEWS HERE
AkzoNobel Share Buyback Program (Week 23 of 2008) June 9, 2008
AkzoNobel (Euronext Amsterdam: AKZ) has announced that, in line with the launch of its €1 billion share buyback program on March 17, 2008, the company has repurchased 1,353,500 ordinary shares in the period June 2 until June 6, 2008. Shares were repurchased at an average price of €52.72.
The €1 billion program is the first tranche of a €3 billion share buyback program.
The total number of shares repurchased under this program to date is 9,437,233 ordinary shares for a total consideration of €502 million
Defensive Strength Secures AkzoNobel Place in Soccer Showpiece
June 6, 2008
Sports fans might well get a kick out of soccer’s forthcoming Euro 2008 championships, but AkzoNobel has already qualified for the next World Cup.
With just two years to go until South Africa stages the showpiece event, work on the ten main stadiums is well underway, and AkzoNobel’s Marine & Protective Coatings business is already part of the line-up, thanks to its outstanding defensive qualities.
Around 750,000 liters of the company’s International Paint products have been used to provide a protective coating for more than 30,000 tons of steel in three brand new venues. International has also supplied coatings for five existing facilities which are being extended, including the Soccer City stadium in Johannesburg – which will host the final on July 11, 2010.
“This is a huge project,” explains Terry Gilhooley, Protective Coatings Manager with responsibility for Germany, where some of the steel is being fabricated and coated. “It’s also great proof of the quality of our products and our ability to offer truly global solutions in conjunction with our South African distributor, Plascon Paint.”
He adds that a factor crucial in many sports has been vital. “Teamwork has been the key to our success, with interaction taking place between our European, American, South African and Middle Eastern operations. We’ve supplied primer, undercoat and topcoat, which will protect approximately 600,000 square meters of steel in the new stadiums against corrosion and other damaging environmental influences for at least the next 30 years.”
The three new venues being coated by AkzoNobel are in Durban, Port Elizabeth and Cape Town, and it’s the Durban stadium which grabs the architectural limelight. Its roof support is a 100-meter high, 350-meter wide dual steel arch made up of 56 individual sections – all of which are protected with International Paint products.
“The sections weigh up to 115 tons each and are actually being fabricated in Hanover and Johannesburg and will be transported to Durban by ship and road respectively, before being assembled on site,” continues Gilhooley.
AkzoNobel is certainly world class when it comes to coating major sporting venues.
Düsseldorf’s Rhein Stadium and several English Premier League soccer stadiums have also used complete coating systems supplied by International Paints. Other sporting venues to have used the company’s coating systems include the main Olympic facilities in Sydney, Greece and Beijing and Wembley Stadium in England.
Supporting critical Phase I-III clinical studies by outsourcing supporting elements such as bioanalysis.
Dr Vikki Renwick, Pharmaceutical Services Sales Manager for Tepnel Research Products and Services, looks at the trends within the pharmaceutical industry for outsourcing, the challenges facing the industry when looking to outsource difficult services such as bioanalysis, and the critical factors for identifying the ideal outsourcing partner and for building an accretive and rewarding relationship.
Best Practices for Validation of Immunoassays for use in Quantitative Bioanalytical Methods
Emma Waite, Biopharmaceutical Laboratory Manager for Tepnel Research Products and Services reviews the progress and evolution of the guidelines on the validation of immunoassays and discusses the major issues related to their validation and how they differ from chromatographic assays.
Stability Testing of Biopharmaceuticals
Since 2005, the rate of approvals of biopharmaceuticals has slowed down. Dave Scott, General Manager, Tepnel Research Products & Services, investigates some of the considerations which must be taken into account when stability testing biological derived drugs.
The Case for Genotyping In Drug Development
Dr Steve Dodsworth, Director of Molecular Genetic Services at Tepnel Research Products & Services argues the case for genotyping in clinical trials, looking at why pharmaceutical companies should and need to consider genotyping in a trial.
International Technology Transfer – By Design -IPI
By Ronald D. Snee, Ph.D. Principal, Tunnell Consulting William Reilly, Jr Managing Consultant, Tunnell Consulting Chester A. Meyers, Ph.D.Managing Consultant, Tunnell Consulting.
In the relentless drive for greater operational efficiencies, market penetration, optimal capacity utilization, and global agility, more
and more pharmaceutical companies face the unique challenges of international technology transfer. Government regulations, tax
benefits, and mergers and acquisitions are also helping make international technology transfer a required competency for more
and more companies. Whether the transfer is intra-company, inter-company, or to a contract manufacturing organization (CMO);
whether it involves active pharmaceutical ingredients, in-process material, finished product or analytical methods; and whether
the product is in early development, postapproval, or any stage in between in its lifecycle, the ability to perform international
transfer faster, more reliably, and cost-effectively can generate significant competitive and operational advantages.
How to Conduct an Audit of an Outsourcing Provider
Andy McCallum, QA Manager for Tepnel Research Products & Services’ pharmaceutical outsourcing division, provides a guideline for conducting an audit of an outsourcing provider, giving a useful summary of the process, highlighting the main points and demonstrating the many issues to be considered as a part of the supplier approval process.
making the world a better place
INTERLAB (Munich, Germany), the German central laboratory with global operations, increases its European staff to address the expected additional business generated by two US competitors pulling out of the European market and a third laboratory closing down its German lab facilities. These recent developments will allow INTERLAB to grow above the expected rate of 35% in 2009. The German central laboratory with global operations INTERLAB (Munich, Germany) increases its European staff to address the expected additional business generated by two US
competitors pulling out of the European market and a third laboratory closing down its German lab facilities. These recent developments will allow INTERLAB to grow above the expected rate of 35% in 2009.
INTERLAB (Munich, Germany), the German central laboratory with global operations, increases its European project and data management team by 30% to address the expected additional business generated by two US competitors pulling out of the European market and a third laboratory closing down its German lab facilities. These recent developments will allow INTERLAB to grow above the expected rate of 35% in 2009. INTERLAB is providing global central lab services since 1994. Since 2006 China and India are covered as the most recent regions. Additional services provided by INTERLAB include visit-kit building, extended storage of frozen samples and rental/purchase of centrifuges and freezers.
Somerset, NJ – March 5, 2009 — Catalent Pharma Solutions, Inc. announced today the appointment of John Chiminski as President and Chief Executive Officer, effective March 17, 2009. Mr. Chiminski will also serve as a member of the board of directors of Catalent. George Fotiades, who has been serving as President and Chief Executive Officer on an interim basis, will step down from the role effective the same date, but will continue to serve as Chairman of Catalent’s board of directors.
Mr. Chiminski, 45, most recently served as the President and Chief Executive Officer of GE Medical Diagnostics, a $1.9 billion division of GE Healthcare and the world leader in diagnostic imaging agents. In his twenty-one year tenure at GE, Mr. Chiminski has held senior management positions of increasing responsibility in a number of businesses, with a proven track record of driving new product innovation, operational performance improvements, and global growth. Mr. Chiminski received a Bachelor of Science from Michigan State University and a Master of Science from Purdue University, both in electrical engineering, as well as a Master of Management degree from the Kellogg School of Management at Northwestern University.
George Fotiades, Chairman of the Board and interim President and CEO, said, “I am pleased to welcome John to the Catalent executive team. He is an exceptional leader with a passion for serving the customer. His proven track record in innovation, operational excellence and achieving superior performance with global businesses is ideally suited to driving Catalent to reach its full potential.”
“I’m thrilled to be joining Catalent, a great business with a history of innovation and service excellence” Mr. Chiminski noted. “Catalent has unique technologies, a strong market position, and highly committed people around the world. I look forward to working with the Catalent team to extend these advantages to meet the growing needs of our customers.”
About Catalent
Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a leading provider of advanced technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,100 at more than 30 facilities worldwide and in fiscal 2008 generated more than $1.8 billion of annual revenue. For more information, visit www.catalent.com.
Media Contact - Patricia McGee
+1 (732) 537-6407
patricia.mcgee@catalent.com
ApopLogic Pharmaceuticals
biotech company focusing on the development of compounds for the treatment of cancer.
Aursos
biotech company engaged in the development of products- treatment of osteoporosis.
Balboa Biosciences
developing therapeutics- disorders affecting the Central Nervous System.
BSP Pharma
developing products based on natural ingredients including-the fruit of the shea tree.
Chakra Biotech
developing drugs for CNS problems and disorders.
Falco Biotherapeutics
developing therapeutics using ElCam technology.
iQur
detection, monitoring and treatment of viral liver disease.
Mentor
suppliers of surgical aesthetic products, cosmetic dermatological products to plastic surgeons.
Migco Pharmaceuticals
developing treatments for diseases of the nervous system.
Navitas Pharma
developing products, treatment of cardiovascular and metabolic disorders.
Nexigen
developing its own pipeline of therapeutic peptides.
Orcrist Bio
developing therapeutics- stem cell mobilization technologies.
Sepal Pharma
developing- jasmonate-derived anticancers.
Silamed
developing anticancers using silicon medicinal chemistry platform to improve the activity of new and existing compounds.
TCA Cellular Therapy
developing stem cell therapies for neurological diseases such as spinal chord injuries, Parkinson’s disease and amyotropic lateral sclerosis.
Tiltan Pharma
developing antiangiogenic-cancer therapies.
Theravida
developing products for urological and CNS disorders.
TransDerm
developing nucleic acid-based therapies to inhibit target gene expression in skin, including RNAi agents.
ViraBiotech
developing a biological prophylactic universal ant-influenza treatment.
CATALENT PHARMA SOLUTIONS CELEBRATES
75 YEARS OF SOFTGEL INNOVATION IN 2009
Somerset, NJ – April 9, 2009 — Catalent Pharma Solutions, Inc., this year celebrates the seventy-fifth anniversary of the grant of the patent which revolutionized softgel manufacturing, and its seventy-five year heritage of continuous softgel innovation. Catalent will recognize this anniversary by offering a series of publications, technical seminars and celebrations throughout the year.
Softgel capsules encapsulate liquid, paste or oil-based active compounds in solution or suspension into an outer shell, which is sealed simultaneously with filling. Softgels have historically been used to solve formulation challenges, to improve clinical/patient performance of compounds, to provide safe handling for hormonal, potent and cytotoxic drugs, and to provide important market differentiation. Softgels are a preferred dose form in consumer/patient surveys, and physician research suggests that patient preferences may lead to improved medication adherence. Catalent provides softgels for prescription, over-the-counter, vitamin/mineral/supplement, and cosmetic/cosmeceutical customers and applications.
The ground-breaking patent, granted to Robert Pauli Scherer in August 1934, established a new way to manufacture softgels using a rotary die process. This new approach dramatically improved quality and exponentially increased output, while at the same time significantly lowering costs versus the prior method of making capsules, patented one hundred years earlier. Mr. Scherer established a company in Detroit to commercialze the technology, known as Gelatin Products Corporation, which in 1947 was renamed R.P. Scherer Corporation.
Today, Catalent’s Oral Technologies segment carries forward the R.P. Scherer heritage of both scientific and manufacturing innovation, with more than 600 currently active softgel patents and patent applications. Catalent most recently launched a next generation capsule shell, Vegicaps® Soft, produced completely from plant-derived materials, which further expanded softgel compatibility, and addressed the needs of specific patient/consumer sub-populations.
Thomas Stuart, Group President of Catalent’s Oral Technologies business, said, “We’re pleased to have reached this important milestone for the technology and the business. Since I joined the former R.P. Scherer in 1990, we’ve introduced many important formulation and manufacturing innovations for the softgel platform. Even more importantly, during this same time we have brought to market hundreds of important pharmaceutical and consumer health products for our customers, which have improved the lives of patients/consumers around the world.”
Stuart continued, “We expect that the softgel platform’s proven advantage in delivering compounds with limited aqueous solubility will be increasingly valuable to drug developers, and that the consistently proven patient/consumer preference for softgels will be increasingly important for clinical and marketing purposes. And we believe that Catalent’s long heritage of experience, know-how and expertise in formulation and manufacturing, combined with our unrelenting focus on meaningful softgel innovation, will continue to make Catalent the industry’s preferred softgel partner in the future.”
For more information about Catalent’s softgel offerings, or about our 75th Anniversary-related activities, visit www.catalent.com/softgel75.
About Catalent
Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a leading provider of advanced technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,100 at 30 facilities worldwide and in fiscal 2008 generated more than $1.8 billion of annual revenue. For more information, visit www.catalent.com.
International Pharmaceutical Publishers
NEWS
New
Companies
